Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect. Sodium glucose cotransporter 2 (SGLT2) inhibitors, first approved to treat type ...

Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: ...

Bristol-Myers Squibb and AstraZeneca announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin demonstrated significant reductions in HbA1C compared with ...

Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...

Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed. The ...

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ...

Regardless of diabetes status, patients with chronic kidney disease (CKD) have better renal and cardiovascular outcomes as well as a lower chance of dying when dapagliflozin (Farxiga; AstraZeneca) is ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

Amit Bansal, Managing Director, Theon Pharmaceuticals Ltd says this fixed-dose combination tablet of linagliptin, dapagliflozin, and metformin hydrochloride is a suitable option for the following ...

London, UK, Monday 12 December 2022 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain ...

The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. We randomly ...

Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently ...